Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report

Figure 3 Chest positron emission tomography - computed tomography (lung window) after 9 cycles of pembrolizumab, with the yellow arrow pointing to an fluorodeoxyglucose-avid 5. 5 cm × 4 cm mass in the left upper lobe, with central necrosis and a maximum standardized uptake value of 8.6, consistent with malignancy. Inferiorly and in its continuation, there is a second lesion measuring 2.3 cm × 1.8 cm with a maximum standardized uptake value of 7.2, interpreted as a remnant from the initial tumor.